Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information



235 East 42nd Street
New York, NY, 10017


Senior Director
Executive Vice President


Pfizer Venture Investments

Pfizer Venture Investments (PVI) serves as the venture capital arm of Pfizer, supporting a variety of worldwide business development (WWBD) activities. Using Pfizer capital, they invest in innovative healthcare businesses offering new technology platforms that align with their company’s strategic direction. They actively support companies—both financially and as board representatives—as appropriate.

Recent Milestones


Company Date Round Size Participants
RefleXion Medical 4/2014Series A$11.6M3
NeuMoDx Molecular 4/2014Series B$21M4
MISSION Therapeutics 11/2013Series B£20M4
Biodesy 10/2013Series A$15M3
Merus 10/2013Series B€31M5
Cydan 4/2013Venture Round$16M3
Aquinox Pharmaceuticals 4/2013Series C$18M5
Rhythm Pharmaceuticals 11/2012Series B$8M5
Epic Sciences 11/2012Series B$13M3
Ziarco Pharma 11/2012Series A$6M2
Mirna Therapeutics 10/2012Series C$34.5M5
Mersana Therapeutics 7/2012Series A$27M4
Celladon 2/2012Venture Round$43M6
DVS Sciences 7/2011Series A$14.6M3
Neuronetics 5/2011Series E$30M8
TetraLogic Pharmaceuticals 9/2010Series C$5M1
Aquinox Pharmaceuticals 6/2010Series B$25M4
Ablexis 6/2010Series A$12M2
Nodality 3/2010Venture Round$2M2
Flexion Therapeutics 1/2010Series A$9M1
ICAgen 9/2009Venture Round$5M1
Avid Radiopharmaceuticals 5/2009Series D$34.5M8
HD Biosciences 8/2008Series A3
EyeCyte 6/2008Series A$3M1
Five Prime Therapeutics 5/2008Venture Round1
Avid Radiopharmaceuticals 5/2007Series C$26M6
Genizon BioSciences 2/2007Series DC$10M2
Avid Radiopharmaceuticals 1/2006Series A$8.9M4
Coley Pharmaceutical Group 3/2005Venture Round$10M1



  1. RefleXion Medical Raises $11.6M Series A Funding ( [edit]
  2. NeuMoDx Molecular Raises $21M in Series B Financing ( [edit]
  3. Imperial Innovations Group plc : MISSION Therapeutics receives £20m Series B funding ( [edit]
  4. Biodesy Secures $15M in Series A Financing ( [edit]
  5. Merus Raises €31M in Series B Financing ( [edit]
  6. Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities ( [edit]
  7. Aquinox Pharmaceuticals Completes US $18 million Series C Financing ( [edit]
  8. Rhythm Adds $8M to Cap Series B at $33M ( [edit]
  9. Epic Sciences Completes $13M Series B Equity Financing ( [edit]
  10. Ziarco Founded with Series A Financing to Develop First-in Class Anti-inflammatory and Anti-allergic Medicines ( [edit]
  11. Mirna Therapeutics Completes $34.5M Series C Financing ( [edit]
  12. Mersana Therapeutics Raises $27M in Series A-1 Financing ( [edit]
  13. Celladon Closes $43M in Funding ( [edit]
  14. DVS Sciences Completes $14.6M Series A Financing ( [edit]
  15. Neuronetics, Inc. Raises $30 Million in Series E Financing ( [edit]
  16. TetraLogic Pharma Boosts Series C To $37M With Pfizer Ventures Capital ( [edit]
  17. Aquinox Pharmaceuticals completes US $25 million Series B financing ( [edit]
  18. Ablexis, LLC: Series A $12M ( [edit]
  19. Nodality gains backing from Pfizer Ventures in $15.5M round ( [edit]
  20. Flexion Therapeutics Closes $42M Series A Funding and Three in-licensing Deals ( [edit]
  21. Icagen Announces Extension of Pfizer Collaboration ( [edit]
  22. Avid Radiopharmaceuticals Closes $34.5 Million Series D Financing ( [edit]
  23. HD Biosciences Raises First Round ( [edit]
  24. Capital Funding Report [edit]
  25. Capital Funding Report [edit]
  26. Avid RP Closes $26 Million Series C Financing ( [edit]
  28. Avid RP Closes $8.9 Million Financing to Support Development of Alzheimer's Diagnostic and Prognostic Agents ( [edit]
  29. EDGAR [edit]
Edit This Page
Last Edited 4/6/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy